Oral News and Research

RSS

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Combating DVT and PE: Critical recommendations

Three critical recommendations from a national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary embolism (PE), a growing public health problem estimated to affect nearly 1 million Americans each year.

10 Mar 2010

First use of prenatal MRI to detect often-misdiagnosed CCD

In a case believed to be a United States first, the radiology team at Lucile Packard Children's Hospital has used prenatal magnetic resonance imaging to detect an often-misdiagnosed genetic disease.

10 Mar 2010

Augmentation with ketone bodies improves cognitive function in AD patients

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients.

10 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that new data for BMS747158, the company’s novel drug candidate in clinical development as a Positron Emission Tomography (PET) perfusion imaging agent, will be featured in an oral presentation at the American College of Cardiology 59th Annual Scientific Session taking place March 14-16, 2010 in Atlanta.

10 Mar 2010

MicroConstants acquires access to new nanosizing technology

MicroConstants, a GLP-compliant Contract Research Organization specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

SensAble Technologies' digital dentistry product line receives $8M infusion

SensAble Technologies, Inc®, a leading provider of 3D modeling software, haptic devices and dental restoration design and fabrication solutions, announced that it has received an $8 million investment to propel sales, marketing and engineering efforts for its digital dentistry product line. Existing investor HLM Venture Partners led the round and was joined by North Bridge Venture Partners, both of whom are headquartered in the Boston area, and have extensive expertise with medical device company funding.

8 Mar 2010

Genta announces private placement of Convertible Notes for $25M

Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.

8 Mar 2010

National Week of Prayer for the Healing of AIDS in the U.S. and the World

The National Week of Prayer for the Healing of AIDS begins Sunday, March 7th – Saturday, March 13th, 2010, with Churches, Synagogues, Temples and Homes calling Americans to teach, advocate and pray for the healing of AIDS in the United States and the World.

8 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.

8 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically increased in health care institutions for inappropriate indications, route of administration and length of treatment. This is associated with an increased cost burden, increased risk of IV related infections, and utilization of hospital resources.

6 Mar 2010

Rutgers-Camden professor earns NEH grant to study history of babies in modern America

Parents have sought advice on infant-care practices for generations, but a Rutgers-Camden professor is uncovering how those methods have evolved and influenced American culture.

6 Mar 2010

'Had Sex': Different perceptions

When people say they "had sex," what transpired is anyone's guess. A new study from the Kinsey Institute at Indiana University found that no uniform consensus existed when a representative sample of 18- to 96-year-olds was asked what the term meant to them.

5 Mar 2010

People with skin of color more prone to dermatologic problems than those with lighter skin tones

According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.

5 Mar 2010

TLR's role in HIV-1 reactivation induced by periodontal pathogens

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher O.A. Gonzalez (University of Kentucky, Lexington) will present a poster of a study titled "TLR2 and TLR9 Activation by Periodontal Pathogens induce HIV-1 Reactivation."

5 Mar 2010

Paralyzed Veterans: Much more needs to be done for America's veterans with disabilities

Today, Paralyzed Veterans of America National President Gene A. Crayton praised Congressional leaders for making Department of Veterans Affairs healthcare funding an advance appropriation, but urged that much more needs to be done for our nation's veterans with disabilities.

5 Mar 2010

Oral News and Research

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Combating DVT and PE: Critical recommendations

First use of prenatal MRI to detect often-misdiagnosed CCD

Augmentation with ketone bodies improves cognitive function in AD patients

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

MicroConstants acquires access to new nanosizing technology

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

SensAble Technologies' digital dentistry product line receives $8M infusion

Genta announces private placement of Convertible Notes for $25M

National Week of Prayer for the Healing of AIDS in the U.S. and the World

MS Awareness Week: Time for nation to go orange and move it to end MS

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Rutgers-Camden professor earns NEH grant to study history of babies in modern America

'Had Sex': Different perceptions

People with skin of color more prone to dermatologic problems than those with lighter skin tones

TLR's role in HIV-1 reactivation induced by periodontal pathogens

Paralyzed Veterans: Much more needs to be done for America's veterans with disabilities

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News